US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Incyte Corporation - Common Stock (NQ:INCY)

115.30 -1.84 (-1.57%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
News headline image
Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA
From Incyte
Via Business Wire
News headline image
Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025
From Incyte
Via Business Wire
News headline image
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Incyte Corporation
Via Business Wire
News headline image
2 S&P 500 Stocks Worth Investigating and 1 We Brush Off
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth,... 
Via StockStory
Topics Stocks
News headline image
Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding
From Incyte
Via Business Wire
News headline image
Gapping S&P500 stocks in Monday's session ↗
Curious about the S&P500 stocks that are gapping on Monday? Explore the gap up and gap down stocks in the S&P500 index during today's session. 
Via Chartmill
News headline image
Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel
From Incyte
Via Business Wire
News headline image
Top S&P500 movers in Friday's session ↗
Let's delve into the developments on the US markets one hour before the close of the markets on Friday. Below, you'll find the top gainers and losers within the S&P500 index during today's session. 
Via Chartmill
News headline image
Gapping S&P500 stocks in Friday's session ↗
Curious about the S&P500 stocks that are gapping on Friday? Explore the gap up and gap down stocks in the S&P500 index during today's session. 
Via Chartmill
News headline image
INCYTE CORP (NASDAQ:INCY) Fits Minervini Trend Template with Strong Growth Momentum ↗
INCYTE stock shows strong technical uptrends per Minervini's Trend Template, backed by accelerating earnings and revenue growth for high momentum. 
Via Chartmill
News headline image
2 Growth Stocks Set to Flourishand 1 Facing Challenges
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle. 
Via StockStory
News headline image
Integra LifeSciences, Evolent Health, Incyte, iRhythm, and Clover Health Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after a report revealed that the White House plans to pitch a two-year extension of Obamacare subsidies. 
Via StockStory
Topics Economy
News headline image
Q3 Earnings Highs And Lows: Exact Sciences (NASDAQ:EXAS) Vs The Rest Of The Immuno-Oncology Stocks
As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the immuno-oncology industry, including Exact Sciences (NASDAQ:EXAS) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Unpopular Stock That Deserves Some Love and 2 Facing Headwinds
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other... 
Via StockStory
News headline image
Spotting Winners: Natera (NASDAQ:NTRA) And Immuno-Oncology Stocks In Q3
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Natera (NASDAQ:NTRA) and the... 
Via StockStory
Topics Artificial Intelligence
News headline image
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
News headline image
Top S&P500 movers in Tuesday's pre-market session ↗
Discover the top S&P500 movers in Tuesday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
INCYTE CORP (NASDAQ:INCY) Presents a Compelling Case for Value Investors ↗
INCYTE CORP (INCY) is a strong value investing candidate with a low P/E ratio, a healthy balance sheet, and solid profitability, suggesting it's an undervalued stock. 
Via Chartmill
News headline image
This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why ↗
A healthcare hedge fund just trimmed its biggest holding—right as the company posts a clinical and financial breakout year. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally ↗
A healthcare hedge fund just locked in gains on one of its biggest winners—here’s what that move really signals. 
Via The Motley Fool
News headline image
Fear Of An AI Bubble? This Sector Is Quietly Surging While Tech Sinks ↗
While AI stocks slide, healthcare is soaring. XLV leads November gains, outperforming tech as investors rotate. 
Via Benzinga
Topics Artificial Intelligence
News headline image
1 Mid-Cap Stock to Consider Right Now and 2 We Turn Down
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with... 
Via StockStory
News headline image
Peering Into Incyte Corp's Recent Short Interest ↗
 
Via Benzinga
News headline image
Incyte (NASDAQ:INCY) Q3 Earnings: Leading The Immuno-Oncology Pack
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q3. Today, we are looking at immuno-oncology stocks, starting with... 
Via StockStory
Topics Artificial Intelligence
News headline image
Winners And Losers Of Q3: Regeneron (NASDAQ:REGN) Vs The Rest Of The Immuno-Oncology Stocks
Looking back on immuno-oncology stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Regeneron (NASDAQ:REGN) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Cash-Producing Stock Worth Your Attention and 2 Facing Headwinds
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
Topics Economy Supply Chain
News headline image
Incyte’s Moments of Clarity Program Expands to Highlight Powerful Patient Stories in Vitiligo and Pediatric Eczema
From Incyte
Via Business Wire
News headline image
Incyte (INCY): Buy, Sell, or Hold Post Q3 Earnings?
The past six months have been a windfall for Incyte’s shareholders. The company’s stock price has jumped 78.7%, setting a new 52-week high of $106.50 per share. This was partly due to its solid... 
Via StockStory
News headline image
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
The 5 Most Interesting Analyst Questions From Incyte’s Q3 Earnings Call
Incyte’s third quarter saw revenue and profit surpass Wall Street’s expectations, yet the market responded negatively. Management identified robust demand for key drugs Jakafi and Opzelura, alongside... 
Via StockStory
Topics Earnings
< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >